Effectiveness of oral mucositis management based on MASCC/ISOO guidelines in pediatric oncology patients: a
Zübeyde Ezgi Erçelik1, Dilek Bayram2, Birgül Erdoğan3
1Faculty of Health Sciences, Department of Nursing, Division of Pediatric Nursing, Bandırma Onyedi Eylül University, Balıkesir, Türkiye.
Purpose:
Although survival rates in childhood cancer have improved with more effective, risk-adapted multimodal treatments, oral mucositis remains one of the most common treatment-related oral complications. This study evaluated the impact of an oral mucositis care protocol on the severity of mucositis.
Methods:
This prospective randomized controlled study was conducted with 30 pediatric oncology patients aged 6 to 18 years. The sample included children with hematologic malignancies (predominantly acute lymphoblastic leukemia) and solid tumors. The data were collected using a descriptive information form, the Children's International Mucositis Evaluation Scale (ChIMES), and the WHO Oral Mucositis Grading Scale. Standard care was applied to the control group. For the intervention group, an oral care protocol was prepared, and the patients received training. The oral care intervention was applied for 14 days and monitored by the researcher. The patients were monitored for oral mucositis on Days 0, 3, 7, and 14. Those in the intervention group received a calendar for documenting their oral care practices.
Results:
The ChIMES scores showed a significant difference between the groups and were lower in the intervention group (z = 0.010; p = 0.011). The WHO scale results revealed significant differences between the groups on Day 7 (Z = -3.106; p = 0.002) and Day 14 (Z = -2.841; p = 0.005).
Conclusion:
At the end of the study, the severity of mucositis was lower in the patients who received the oral mucositis care protocol. It is recommended that a standardized oral care protocol specific to children be developed and that education on oral mucositis care be provided to children and their parents from the beginning of hospitalization.
Clinical Trial Registration:
ClinicalTrials.gov (Identifier: NCT06711315; Registration date: 29 November 2024).
More Related Videos
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Tonsillitis II: Management
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...


